- Home
- ARMN vs TRVI Comparison
ARMN vs TRVI Comparison
Compare ARMN & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMN
- TRVI
- Stock Information
- Founded
- ARMN 1992
- TRVI 2011
- Country
- ARMN Canada
- TRVI United States
- Employees
- ARMN N/A
- TRVI N/A
- Industry
- ARMN
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- ARMN
- TRVI Health Care
- Exchange
- ARMN Nasdaq
- TRVI Nasdaq
- Market Cap
- ARMN 769.7M
- TRVI 725.7M
- IPO Year
- ARMN N/A
- TRVI 2019
- Fundamental
- Price
- ARMN $6.65
- TRVI $5.46
- Analyst Decision
- ARMN
- TRVI Strong Buy
- Analyst Count
- ARMN 0
- TRVI 8
- Target Price
- ARMN N/A
- TRVI $19.31
- AVG Volume (30 Days)
- ARMN 1.9M
- TRVI 2.6M
- Earning Date
- ARMN 08-12-2025
- TRVI 08-07-2025
- Dividend Yield
- ARMN N/A
- TRVI N/A
- EPS Growth
- ARMN 28.55
- TRVI N/A
- EPS
- ARMN 0.15
- TRVI N/A
- Revenue
- ARMN $560,512,000.00
- TRVI N/A
- Revenue This Year
- ARMN $49.45
- TRVI N/A
- Revenue Next Year
- ARMN N/A
- TRVI N/A
- P/E Ratio
- ARMN $42.43
- TRVI N/A
- Revenue Growth
- ARMN 22.28
- TRVI N/A
- 52 Week Low
- ARMN $3.29
- TRVI $2.36
- 52 Week High
- ARMN $7.02
- TRVI $7.48
- Technical
- Relative Strength Index (RSI)
- ARMN 58.15
- TRVI 38.66
- Support Level
- ARMN $6.31
- TRVI $5.53
- Resistance Level
- ARMN $6.91
- TRVI $5.96
- Average True Range (ATR)
- ARMN 0.26
- TRVI 0.33
- MACD
- ARMN -0.03
- TRVI -0.08
- Stochastic Oscillator
- ARMN 71.79
- TRVI 8.46
About ARMN Aris Mining Corporation
Aris Mining Corp is engaged in the acquisition, exploration, development and operation of gold properties in Colombia, Guyana and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, Toroparu Project in Guyana and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.